We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.14 | -0.35% | 39.87 | 1,274 | 09:52:09 |
From Jul 2022 to Jul 2024
By Anthony O. Goriainoff
GSK said Tuesday that the U.S. Food and Drug Administration has accepted the supplemental Biologics License Application for its Jemperli endometrial cancer treatment in combination with chemotherapy.
The London-listed pharmaceutical giant said the FDA has granted the application a priority review which has a Prescription Drug User Fee Act, or PDUFA, action date of Sept. 23.
The PDUFA refers to the date by which the agency's review process must be completed.
The company said that if approved the treatment plus chemotherapy could represent a meaningful front-line treatment advancement for patients with primary advanced or recurrent endometrial cancer.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
June 06, 2023 02:29 ET (06:29 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
